Cited by 118Lysosomal Storage Disorders ResearchGlycogen Storage Diseases and MyoclonusMetabolism and Genetic Disorders

Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect.

Open access
Kretz, K A, Carson, G S, Morimoto, S, Kishimoto, Y, Fluharty, A L, O'Brien, J S·1990·Proceedings of the National Academy of Sciences

Abstract

Saposins are small, heat-stable glycoproteins required for the hydrolysis of sphingolipids by specific lysosomal hydrolases. Saposins A, B, C, and D are derived by proteolytic processing from a single precursor protein named prosaposin. Saposin B, previously known as SAP-1 and sulfatide activator, stimulates the hydrolysis of a wide variety of substrates including cerebroside sulfate, GM1 ganglioside, and globotriaosylceramide by arylsulfatase A, acid beta-galactosidase, and alpha-galactosidase, respectively. Human saposin B deficiency, transmitted as an autosomal recessive trait, results in tissue accumulation of cerebroside sulfate and a clinical picture resembling metachromatic leukodystrophy (activator-deficient metachromatic leukodystrophy). We have examined transformed lymphoblasts from the initially reported saposin B-deficient patient and found normal amounts of saposins A, C, and D. After preparing first-strand cDNA from lymphoblast total RNA, we used the polymerase chain reaction to amplify the prosaposin cDNA. The patient's mRNA differed from the normal sequence by only one C----T transition in the 23rd codon of saposin B, resulting in a threonine to isoleucine amino acid substitution. An affected male sibling has the same mutation as the proband and their heterozygous mother carries both the normal and mutant sequences, providing additional evidence that this base change is the disease-causing mutation. This base change results in the replacement of a polar amino acid (threonine) with a nonpolar amino acid (isoleucine) and, more importantly, eliminates the glycosylation signal in this activator protein. One explanation for the deficiency of saposin B in this disease is that the mutation may increase the degradation of saposin B by exposing a potential proteolytic cleavage site (arginine) two amino acids to the amino-terminal side of the glycosylation site when the carbohydrate side chain is absent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.87.7.2541

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Prosaposin and progranulin are key regulators of lysosomal function, and recessive mutations in either gene can cause separate LSDs.

    “Prosaposin and progranulin are key regulators of lysosomal function, and recessive mutations in either gene can cause separate LSDs32,33.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 24

  1. Beeley J. G. Location of the carbohydrate groups of ovomucoid. Biochem J. 1976 Nov;159(2):335–345. doi: 10.1042/bj1590335. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  2. Beeley J. G. Peptide chain conformation and the glycosylation of glycoproteins. Biochem Biophys Res Commun. 1977 Jun 20;76(4):1051–1055. doi: 10.1016/0006-291x(77)90962-7. [DOI] [PubMed] [Google Scholar] · DOI
  3. Collard M. W., Griswold M. D. Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry. 1987 Jun 16;26(12):3297–3303. doi: 10.1021/bi00386a008. [DOI] [PubMed] [Google Scholar] · DOI
  4. Fischer G., Jatzkewitz H. The activator of cerebroside sulphatase. Purification from human liver and identification as a protein. Hoppe Seylers Z Physiol Chem. 1975 May;356(5):605–613. doi: 10.1515/bchm2.1975.356.1.605. [DOI] [PubMed] [Google Scholar] · DOI
  5. Fischer G., Jatzkewitz H. The activator of cerebroside-sulphatase. A model of the activation. Biochim Biophys Acta. 1978 Jan 27;528(1):69–76. doi: 10.1016/0005-2760(78)90053-x. [DOI] [PubMed] [Google Scholar] · DOI
  6. Fürst W., Machleidt W., Sandhoff K. The precursor of sulfatide activator protein is processed to three different proteins. Biol Chem Hoppe Seyler. 1988 May;369(5):317–328. doi: 10.1515/bchm3.1988.369.1.317. [DOI] [PubMed] [Google Scholar] · DOI
  7. Gärtner S., Conzelmann E., Sandhoff K. Activator protein for the degradation of globotriaosylceramide by human alpha-galactosidase. J Biol Chem. 1983 Oct 25;258(20):12378–12385. [PubMed] [Google Scholar]
  8. Inui K., Emmett M., Wenger D. A. Immunological evidence for deficiency in an activator protein for sulfatide sulfatase in a variant form of metachromatic leukodystrophy. Proc Natl Acad Sci U S A. 1983 May;80(10):3074–3077. doi: 10.1073/pnas.80.10.3074. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  9. Kretz K. A., Carson G. S., O'Brien J. S. Direct sequencing from low-melt agarose with Sequenase. Nucleic Acids Res. 1989 Jul 25;17(14):5864–5864. doi: 10.1093/nar/17.14.5864. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  10. Li S. C., Kihara H., Serizawa S., Li Y. T., Fluharty A. L., Mayes J. S., Shapiro L. J. Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. Deficiency in urine of patients affected with cerebroside sulfatase activator deficiency and identity with activators for the enzymatic hydrolysis of GM1 ganglioside and globotriaosylceramide. J Biol Chem. 1985 Feb 10;260(3):1867–1871. [PubMed] [Google Scholar]
  11. Li S. C., Li Y. T. An activator stimulating the enzymic hydrolysis of sphingoglycolipids. J Biol Chem. 1976 Feb 25;251(4):1159–1163. [PubMed] [Google Scholar]
  12. Li S. C., Sonnino S., Tettamanti G., Li Y. T. Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. J Biol Chem. 1988 May 15;263(14):6588–6591. [PubMed] [Google Scholar]
  13. Li S. C., Wan C. C., Mazzotta M. Y., Li Y. T. Requirement of an activator for the hydrolysis of sphingoglycolipids by glycosidases of human liver. Carbohydr Res. 1974 May;34(1):189–193. doi: 10.1016/s0008-6215(00)80383-3. [DOI] [PubMed] [Google Scholar] · DOI
  14. Mehl E., Jatzkewitz H. Eine Cerebrosidsulfatase aus Schweineniere. Hoppe Seylers Z Physiol Chem. 1964;339(1):260–276. [PubMed] [Google Scholar]
  15. Morimoto S., Martin B. M., Kishimoto Y., O'Brien J. S. Saposin D: a sphingomyelinase activator. Biochem Biophys Res Commun. 1988 Oct 14;156(1):403–410. doi: 10.1016/s0006-291x(88)80855-6. [DOI] [PubMed] [Google Scholar] · DOI
  16. Morimoto S., Martin B. M., Yamamoto Y., Kretz K. A., O'Brien J. S., Kishimoto Y. Saposin A: second cerebrosidase activator protein. Proc Natl Acad Sci U S A. 1989 May;86(9):3389–3393. doi: 10.1073/pnas.86.9.3389. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  17. Nakano T., Sandhoff K., Stümper J., Christomanou H., Suzuki K. Structure of full-length cDNA coding for sulfatide activator, a Co-beta-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J Biochem. 1989 Feb;105(2):152–154. doi: 10.1093/oxfordjournals.jbchem.a122629. [DOI] [PubMed] [Google Scholar] · DOI
  18. O'Brien J. S., Kretz K. A., Dewji N., Wenger D. A., Esch F., Fluharty A. L. Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science. 1988 Aug 26;241(4869):1098–1101. doi: 10.1126/science.2842863. [DOI] [PubMed] [Google Scholar] · DOI
  19. Olden K., Parent J. B., White S. L. Carbohydrate moieties of glycoproteins. A re-evaluation of their function. Biochim Biophys Acta. 1982 May 12;650(4):209–232. doi: 10.1016/0304-4157(82)90017-x. [DOI] [PubMed] [Google Scholar] · DOI
  20. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  21. Sano A., Radin N. S. The carbohydrate moiety of the activator protein for glucosylceramide beta-glucosidase. Biochem Biophys Res Commun. 1988 Aug 15;154(3):1197–1203. doi: 10.1016/0006-291x(88)90267-7. [DOI] [PubMed] [Google Scholar] · DOI
  22. Stevens R. L., Fluharty A. L., Kihara H., Kaback M. M., Shapiro L. J., Marsh B., Sandhoff K., Fischer G. Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy. Am J Hum Genet. 1981 Nov;33(6):900–906. [PMC free article] [PubMed] [Google Scholar]
  23. Wenger D. A., DeGala G., Williams C., Taylor H. A., Stevenson R. E., Pruitt J. R., Miller J., Garen P. D., Balentine J. D. Clinical, pathological, and biochemical studies on an infantile case of sulfatide/GM1 activator protein deficiency. Am J Med Genet. 1989 Jun;33(2):255–265. doi: 10.1002/ajmg.1320330223. [DOI] [PubMed] [Google Scholar] · DOI
  24. Wenger D. A., Sattler M., Roth S. A protein activator of galactosylceramide beta-galactosidase. Biochim Biophys Acta. 1982 Sep 14;712(3):639–649. doi: 10.1016/0005-2760(82)90293-4. [DOI] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Kretz, K. A., Carson, G. S., Morimoto, S., Kishimoto, Y., Fluharty, A. L., & O'Brien, J. S.
Affiliations
  • University of California San Diego (US)
  • University of California, Los Angeles (US)
  • Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla 92093.
Venue
Proceedings of the National Academy of Sciences
Published
1990-04
Volume
87
Issue
7
Pages
2541-2544
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2090565001
Cited by
118
References
0
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 1 · 2012: 3
FWCI
5.38
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hd018983-06, 5r01ns013559-20)
  • National Institute of Neurological Disorders and Stroke (NS-13559, NS-08682)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 18983)
Topics
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
  • Health Sciences › Medicine › Rheumatology › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
saposin B, prosaposin, metachromatic leukodystrophy, proteolytic cleavage sites, autosomal recessive inheritance
MeSH terms
Amino Acid Sequence, Base Sequence, Cloning, Molecular, DNA, Glycoproteins, Glycosylation, Humans, Molecular Sequence Data, Mutation, Protein Processing, Post-Translational, Reference Values, Polymerase Chain Reaction, Sphingolipid Activator Proteins, Saposins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review